MARC details
000 -LEADER |
fixed length control field |
03927nam a22005055i 4500 |
001 - CONTROL NUMBER |
control field |
978-3-031-32815-2 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240729140254.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
231012s2023 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9783031328152 |
-- |
978-3-031-32815-2 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
PSAN |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
SCI089000 |
Source |
bisacsh |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
PSAN |
Source |
thema |
245 10 - TITLE STATEMENT |
Title |
Biomarkers for Huntington's Disease |
Subtitle |
: Improving Clinical Outcomes / |
250 ## - EDITION |
Edition statement |
1st ed. 2023. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Cham : |
Name of producer, publisher, distributor, manufacturer |
Springer International Publishing : |
-- |
Imprint: Springer, |
Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
XVI, 475 p. 42 illus., 39 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
490 1# - SERIES TITLE |
Series statement |
Contemporary Clinical Neuroscience, |
International Standard Serial Number |
2627-5341 |
505 0# - CONTENTS |
Contents |
Molecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends. |
520 ## - ABSTRACT |
Abstract |
Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents adistinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Neurosciences. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Neurology . |
650 #0 - SUBJECT HEADINGS |
Subject term |
Neurophysiology. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Neuropharmacology. |
9 (RLIN) |
7130 |
650 14 - SUBJECT HEADINGS |
Subject term |
Neuroscience. |
650 24 - SUBJECT HEADINGS |
Subject term |
Neurology. |
650 24 - SUBJECT HEADINGS |
Subject term |
Neurophysiology. |
650 24 - SUBJECT HEADINGS |
Subject term |
Neuropharmacology. |
9 (RLIN) |
7130 |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Thomas, Elizabeth A. |
Relator term |
editor. |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Parkin, Georgia M. |
Relator term |
editor. |
710 2# - ADDED CORPORATE NAME |
Added corporate author |
SpringerLink (Online service) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Contemporary Clinical Neuroscience, |
International Standard Serial Number |
2627-5341 |
856 ## - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="#gotoholdings">#gotoholdings</a> |
Link text |
Access resource |
245 ## - TITLE STATEMENT |
Medium |
[E-Book] |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
912 ## - |
-- |
ZDB-2-SBL |
912 ## - |
-- |
ZDB-2-SXB |